Data Sheet (Cat.No.T6185)



Gambogic Acid

Chemical Properties

CAS No.: 2752-65-0

Formula: C38H44O8


Molecular Weight: 628.75

Appearance: no data available

store at low temperature, keep away from direct

Storage: sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Gambogic Acid (Guttic Acid) (EC50=0.78-1.64 uM) activates caspases. Gambogic Acid competitively suppresses Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1. The IC50s of Gambogic Acid for Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 are 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 uM, respectively.
Targets(IC50)	Bcl-2 Family,Autophagy
In vitro	Gambogic Acid is a caged xanthone that is derived from Garcinia hanburyi and functions as a strong apoptotic inducer in many types of cancer cells by inhibiting human Bcl-2 family proteins and activating caspases. Gambogic Acid also blocks Kir2.1 channels with EC50 of \leq 100 nM.[1] [2] [3] Gambogic Acid significantly inhibits human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion, tube formation, and microvessel growth at nM concentration. [4]
In vivo	Gambogic Acid effectively inhibits tumor angiogenesis and suppressed tumor growth with low side effects using metronomic chemotherapy with Gambogic Acid. [4] Gambogic Acid has multiple functional effects including the induction of apoptosis, the inhibition of proliferation and the prevention of cancer metastasis and tumor angiogenesis. [5] In both animal tumor models and Clinicalal trials, Gambogic Acid efficiently inhibits tumor growth with minimal side effects, with little toxicity on immune and hemopoietic systems. Gambogic Acid can produce tissue-specific proteasome inhibition and tumor-specific toxicity. [6] LD50: Mice 45 mg/kg (i.p.). [7]
Kinase Assay	The fluorescence polarization reactions are performed. For Kidetermination, duplicate 200 µL reactions are set up at eight different ATP concentrations from 200 µM (2-fold serial dilutions) in the presence of either DMSO or R406 at 125, 62.5, 31.25, 15.5, or 7.8 nM. At different time points, 20 µL of each reaction is removed and quenched to stop the reaction. For each concentration of R406, the rate of reaction at each concentration of ATP is determined and plotted against the ATP concentration to determine the apparent Km and Vmax (maximal rate). Finally the apparent Km (or apparent Km/Vmax) is plotted against the inhibitor concentration to determine the Ki. All data analysis is performed using Prism and Prism enzyme kinetics programs[1]

Solubility Information

A DRUG SCREENING EXPERT

Calubility	U30. Insolvible		٦
Solubility	H2O: Insoluble		
	DMSO: 47.2 mg/mL (75.07 mM), Sonication is recommended.		
	Ethanol: 62.9 mg/mL (100.04 mM), Sonication is recommended.		
	(< 1 mg/ml refers to the product slightly soluble or insoluble)		

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5905 mL	7.9523 mL	15.9046 mL
5 mM	0.3181 mL	1.5905 mL	3.1809 mL
10 mM	0.159 mL	0.7952 mL	1.5905 mL
50 mM	0.0318 mL	0.159 mL	0.3181 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Zhai D, et al. Mol Cancer Ther, 2008, 7(6), 1639-1646.

Liu X, Hu Q, Wang W, et al. A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ER α mutants in breast cancer. Biochemical Pharmacology. 2021, 188: 114583.

Zhang HZ, et al. Bioorg Med Chem, 2004, 12(2), 309-317.

Pandey MK, et al. Blood, 2007, 110(10), 3517-3525.

Yi T, et al. Cancer Res. 2008 Mar 15;68(6):1843-50.

Wang X, et al. Anticancer Agents Med Chem, 2012, 12(8), 1994-12000.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com